Work

Ivonescimab (PD-1/VEGF bispecific antibody) combined with HAIC for first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm phase II study.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e16212

Authors: Huikai Li, Rentao Li, Xihao Zhang, Xiaojing Xie, Junchao Yao, Yang Liu, Linlin Fu, Qi Qi, Xiaofeng Mu, Yu Bai

Institutions: Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410812737

Cites:

Cited by: 1

Related to: 10